Repligen | RGEN - Cost Of Sales


Repligen reported $94.08M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Agilent USD 852M 19M Dec/2025
Align Technology USD 363.97M 7.48M Dec/2025
Bio Techne USD 104.6M 6.16M Dec/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Bruker USD 528M 46.9M Dec/2025
Charles River Laboratories USD 722.27M 28.81M Dec/2025
Danaher USD 2.87B 342M Dec/2025
Dentsply International USD 518M 55M Dec/2025
General Electric Aerospace USD 8.92B 654M Dec/2025
Henry Schein USD 2.44B 62M Dec/2025
Illumina USD 400M 49M Dec/2025
IQVIA Holdings USD 3.24B 518M Dec/2025
Mettler Toledo International USD 473.97M 33.71M Dec/2025
Myriad Genetics USD 63M 1.1M Dec/2025
OraSure Technologies USD 15.43M 113K Dec/2025
Pacific Biosciences Of California USD 28.9M 10M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Repligen USD 94.08M 5.79M Dec/2025
Revvity USD 350.4M 26.05M Dec/2025
Standard Biotools USD 12.41M 2.34M Dec/2025
Thermo Fisher Scientific USD 7.58B 674M Dec/2025
Waters USD 374.94M 47.13M Dec/2025
West Pharmaceutical Services USD 501.1M 9.2M Dec/2025